Vaxcyte Inc. (PCVX)
NASDAQ: PCVX
· Real-Time Price · USD
33.38
0.51 (1.55%)
At close: Jun 23, 2025, 1:53 PM
1.55% (1D)
| Bid | 33.35 |
| Market Cap | 4.31B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -509.63M |
| EPS (ttm) | -3.99 |
| PE Ratio (ttm) | -8.37 |
| Forward PE | -7.44 |
| Analyst | Buy |
| Ask | 33.42 |
| Volume | 366,403 |
| Avg. Volume (20D) | 2,553,312 |
| Open | 32.64 |
| Previous Close | 32.87 |
| Day's Range | 32.43 - 33.40 |
| 52-Week Range | 27.66 - 121.06 |
| Beta | 1.20 |
About PCVX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PCVX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PCVX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+14.17%
Shares of vaccine stocks are trading higher follow...
Unlock content with
Pro Subscription
1 month ago
+8.45%
Vaxcyte shares are trading higher after the company reported better-than-expected Q1 EPS results.
2 months ago · seekingalpha.com
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying OpportunityVaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It...
